|
WO2017193046A1
(en)
|
2016-05-06 |
2017-11-09 |
Sage Therapeutics, Inc. |
Oxysterols and methods of use thereof
|
|
CN110944651A
(zh)
|
2017-02-08 |
2020-03-31 |
蜻蜓疗法股份有限公司 |
用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
|
|
EP4273258A3
(en)
|
2017-02-20 |
2024-01-17 |
Dragonfly Therapeutics, Inc. |
Proteins binding her2, nkg2d and cd16
|
|
EP3585817A4
(en)
*
|
2017-02-22 |
2020-12-02 |
Aleta Biotherapeutics Inc. |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
|
|
WO2018156791A1
(en)
*
|
2017-02-22 |
2018-08-30 |
Aleta Biotherapeutics Inc. |
Compositions and methods for tumor transduction
|
|
JP7054418B2
(ja)
|
2017-11-08 |
2022-04-13 |
ビオンテック ユーエス インコーポレイテッド |
T細胞を製造する組成物及び方法
|
|
CN111315405A
(zh)
*
|
2017-11-09 |
2020-06-19 |
免疫医疗有限责任公司 |
双特异性融合多肽及其使用方法
|
|
MX2020008333A
(es)
|
2018-02-08 |
2020-09-21 |
Dragonfly Therapeutics Inc |
Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
|
|
CA3090244A1
(en)
|
2018-02-08 |
2019-08-15 |
Dragonfly Therapeutics, Inc. |
Antibody variable domains targeting the nkg2d receptor
|
|
CN112119093A
(zh)
|
2018-02-20 |
2020-12-22 |
蜻蜓治疗公司 |
结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法
|
|
US11267864B2
(en)
|
2018-02-26 |
2022-03-08 |
Medigene Immunotherapies Gmbh |
Nyeso tcr
|
|
JP2021523140A
(ja)
*
|
2018-05-07 |
2021-09-02 |
ドラゴンフライ セラピューティクス, インコーポレイテッド |
Nkg2d、cd16、及び腫瘍関連抗原に結合するタンパク質
|
|
CN110507824A
(zh)
*
|
2018-05-21 |
2019-11-29 |
荣昌生物制药(烟台)有限公司 |
一种抗间皮素抗体及其抗体药物缀合物
|
|
PE20210320A1
(es)
|
2018-06-01 |
2021-02-16 |
Novartis Ag |
Moleculas de union contra bcma y usos de las mismas
|
|
CA3108427A1
(en)
|
2018-08-08 |
2020-02-13 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
CN113164570B
(zh)
|
2018-08-08 |
2024-05-14 |
蜻蜓疗法股份有限公司 |
结合nkg2d、cd16和肿瘤相关抗原的蛋白质
|
|
WO2020084608A1
(en)
*
|
2018-10-22 |
2020-04-30 |
Explore Bio 1 Ltd |
Precursor bispecific antibody constructs and methods of use thereof
|
|
SG11202104180WA
(en)
*
|
2018-10-30 |
2021-05-28 |
Peter Maccallum Cancer Inst |
Bispecific polypeptides for engagement of car expressing immune cells with antigen presenting cells and uses thereof
|
|
EP4578507A3
(en)
*
|
2018-11-01 |
2025-11-12 |
Gracell Biotechnologies (Shanghai) Co., Ltd. |
Compositions and methods for t cell engineering
|
|
WO2020123964A1
(en)
|
2018-12-13 |
2020-06-18 |
Labyrx Immunologic Therapeutics (Usa) Limited |
Labyrinthin-based peptides for cancer immunotherapies and uses thereof
|
|
CN113993892A
(zh)
*
|
2019-01-08 |
2022-01-28 |
莱比锡免疫治疗(美国)有限公司 |
靶向迷路蛋白或其部分的构建体以及所述构建体的用途
|
|
WO2020172259A1
(en)
*
|
2019-02-20 |
2020-08-27 |
Research Institute At Nationwide Children's Hospital |
Cancer-targeted, virus-encoded, regulatable t (catvert) or nk cell (catvern) linkers
|
|
TWI867324B
(zh)
|
2019-05-08 |
2024-12-21 |
美商百歐恩泰美國公司 |
T細胞製備組合物及方法
|
|
AU2020279224B2
(en)
|
2019-05-21 |
2024-12-05 |
Novartis Ag |
Trispecific binding molecules against BCMA and uses thereof
|
|
UY38701A
(es)
|
2019-05-21 |
2020-12-31 |
Novartis Ag |
Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
|
|
DK3993876T3
(en)
|
2019-07-01 |
2024-12-02 |
Tonix Pharma Ltd |
Anti-cd154 antibodies and uses thereof
|
|
WO2021057906A1
(zh)
*
|
2019-09-25 |
2021-04-01 |
科济生物医药(上海)有限公司 |
表达il-15的免疫效应细胞
|
|
CN111235113A
(zh)
*
|
2020-01-21 |
2020-06-05 |
南京北恒生物科技有限公司 |
包含嵌合抗原受体的免疫细胞及其用途
|
|
AU2021268340A1
(en)
|
2020-05-06 |
2022-12-08 |
Dragonfly Therapeutics, Inc. |
Proteins binding NKG2D, CD16 and CLEC12A
|
|
GB202008688D0
(en)
*
|
2020-06-09 |
2020-07-22 |
Cancer Research Tech Ltd |
Chimeric antigen receptor cell
|
|
JP2023541694A
(ja)
*
|
2020-09-22 |
2023-10-03 |
ワールド バイオテック リジェネラティブ メディカル グループ リミテッド |
がん治療剤としての二重特異的抗原結合分子を有するcar発現ナチュラルキラー細胞の生成方法及び組成物
|
|
AU2022205313A1
(en)
|
2021-01-06 |
2023-07-20 |
Tonix Pharma Limited |
Methods of inducing immune tolerance with modified anti-cd154 antibodies
|
|
EP4301774A4
(en)
|
2021-03-03 |
2025-08-13 |
Dragonfly Therapeutics Inc |
METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
|
|
EP4351588A1
(en)
|
2021-06-11 |
2024-04-17 |
Sage Therapeutics, Inc. |
Neuroactive steroid for the treatment of alzheimer's disease
|
|
CA3231174A1
(en)
*
|
2021-08-02 |
2023-02-09 |
Innovent Biologics (Suzhou) Co., Ltd. |
Anti-cd79bxcd3 bispecific antibody and use thereof
|
|
CN115975027B
(zh)
*
|
2021-08-12 |
2023-10-20 |
广东东阳光药业股份有限公司 |
Il-11人源化抗体及其应用
|
|
CA3233085A1
(en)
*
|
2021-09-24 |
2023-03-30 |
Synergy Imt, Inc. |
Composition of recombinant antigen binding molecules and method of making and using thereof
|
|
TW202340474A
(zh)
*
|
2022-01-11 |
2023-10-16 |
大陸商深圳市珈鈺生物科技有限公司 |
樹突細胞腫瘤疫苗和其用途
|
|
CN115368446B
(zh)
*
|
2022-07-19 |
2025-08-08 |
合肥天港免疫药物有限公司 |
双特异性抗体及其应用
|
|
JP2026502768A
(ja)
|
2022-10-25 |
2026-01-27 |
アブレクシス, エルエルシー |
抗cd3抗体
|
|
WO2024107731A2
(en)
|
2022-11-14 |
2024-05-23 |
Ablexis, Llc |
Anti-pd-l1 antibodies
|
|
WO2024182516A1
(en)
*
|
2023-02-28 |
2024-09-06 |
Juno Therapeutics, Inc. |
Cell therapy for treating systemic autoimmune diseases
|
|
TW202547884A
(zh)
*
|
2024-03-15 |
2025-12-16 |
美商艾爾維克醫療公司 |
Muc16/napi-2b抗體及使用方法
|
|
CN117965633A
(zh)
*
|
2024-04-01 |
2024-05-03 |
北京双赢科创生物科技有限公司 |
一种IFNγ受体敲除的CAR-T细胞的制备方法与应用
|
|
WO2025248134A1
(en)
|
2024-05-31 |
2025-12-04 |
Tonix Pharma Limited |
Treatment methods comprising administration of modified cd154 antibodies
|
|
CN122071528A
(zh)
*
|
2024-11-22 |
2026-05-22 |
浙江纳米抗体技术中心有限公司 |
多特异性抗原结合分子及其应用
|
|
WO2026152120A2
(en)
|
2025-01-13 |
2026-07-16 |
HCW Biologics, Inc. |
Chimeric polypeptides and uses thereof
|